^
Association details:
| Biomarker: | MGMT unmethylation |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | UCPVax (Immunostimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Anti-telomerase vaccine in patients with newly diagnosed, unmethylated MGMT glioblastoma: A phase II study.
Published date:
05/25/2023
Excerpt:
In the intent-to-treat population (n=31), the PFS was 8.9 months (95% CI: 7.6–10.6) and the median OS was 17.9 months (95% CI: 16–23)....UCPVax is highly immunogenic and provides an interesting OS rate in this population of poor prognosis, unmethylated MGMT GBM patients.
DOI:
10.1200/JCO.2023.41.16_suppl.2005
Trial ID:
